4
Clinical Trials associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University)Clinical study of B7H3 CAR-T combined with oncolytic adenovirus injection in the treatment of recurrent and refractory gastrointestinal neoplasms
Prospective clinical study of the safety and efficacy of anti-B7-H3 CAR T cells in the treatment of relapsed, refractory acute myeloid leukemia
Start Date01 Apr 2022 |
Sponsor / Collaborator- |
A Single-Arm, Open-Label Study to Evaluate Safety and Efficacy of B7H3 or HBsAg Targeting CAR-T in Treating Advanced Hepatocellular Carcinoma
This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.
100 Clinical Results associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University)
100 Translational Medicine associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University)
100 Patents (Medical) associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University)
100 Deals associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University)